NLS Pharmaceutics (NASDAQ:NCEL) vs. 4D Molecular Therapeutics (NASDAQ:FDMT) Head-To-Head Comparison

NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

NLS Pharmaceutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.99, indicating that its stock price is 199% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for NLS Pharmaceutics and 4D Molecular Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1	0	0	0	1.00
4D Molecular Therapeutics	1	1	8	0	2.70

4D Molecular Therapeutics has a consensus target price of $33.25, indicating a potential upside of 323.03%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than NLS Pharmaceutics.

Profitability

This table compares NLS Pharmaceutics and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
4D Molecular Therapeutics	-174,314.17%	-47.27%	-42.39%

Valuation & Earnings

This table compares NLS Pharmaceutics and 4D Molecular Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A
4D Molecular Therapeutics	$40,000.00	11,226.05	-$160.87 million	($3.75)	-2.10

NLS Pharmaceutics has higher earnings, but lower revenue than 4D Molecular Therapeutics.

Summary

4D Molecular Therapeutics beats NLS Pharmaceutics on 6 of the 11 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.